StemCells Inc. (STEM) Announces Webcast to Discuss Pelizaeus-Merzbacher Disease Clinical Trial Results
4/2/2012 10:00:39 AM
NEWARK, Calif., March 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it will host a conference call and webcast to discuss results from its Phase I clinical trial in Pelizaeus-Merzbacher Disease (PMD) on Monday, April 2, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time). A summary of the trial results will be presented on Saturday, March 31, at the 2012 European Leukodystrophy Association (ELA) Families/Scientists Meeting in Paris. The Phase I trial was completed in February 2012, and was designed to assess the safety and preliminary efficacy of the Company's proprietary HuCNS-SC® cells (purified human neural stem cells) as a potential treatment for PMD, a rare hypo-myelination disorder in children.